Compare ULCC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | PCRX |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2017 | 2010 |
| Metric | ULCC | PCRX |
|---|---|---|
| Price | $7.09 | $22.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $5.21 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 4.5M | 359.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $3,724,000,000.00 | $541,533,000.00 |
| Revenue This Year | $23.76 | $6.78 |
| Revenue Next Year | $11.48 | $8.54 |
| P/E Ratio | ★ N/A | $324.00 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $3.02 | $18.80 |
| 52 Week High | $7.11 | $27.64 |
| Indicator | ULCC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 70.18 | 41.76 |
| Support Level | $4.58 | $22.04 |
| Resistance Level | N/A | $23.97 |
| Average True Range (ATR) | 0.44 | 0.74 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 91.51 | 21.43 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos, and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. The majority of revenue is from Domestic flight follow by International.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.